Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06464510 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Norepinephrine and Vasopressin for Rescue Versus Early Vasopressin for Vasopressor Dependent Sepsis

Study acronym: NoVa
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site details revised at 2 of 8 sites
    • Collaborators: 1 to 2
    • Eligibility criteria expanded, about 5 words
    v5
  2. Start date changed from estimate of Oct 2024 to Nov 21, 2024
    • Eligibility criteria expanded, about 27 words
    v4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jul 2024 to Oct 2024
    • Study sites: 9 to 8
    v3
  4. Interventions: Vasopressin (Drug) to Early Vasopressin (Drug), Norepinephrine and Vasopressin for Rescue (Drug)v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The norepinephrine and vasopressin for rescue versus early vasopressin for vasopressor dependent sepsis (NoVa) is a phase 3, multicenter, open-label, randomized controlled trial comparing an early vasopressin initiation strategy versus norepinephrine plus vasopressin initiation only as a rescue strategy for hemodynamic management of critically ill patients with vasopressor dependent sepsis.
Trial Details
NCT Number NCT06464510
Lead Sponsor Hospital do Coracao
Collaborators: Brazilian Research In Intensive Care Network, National Institute of Science and Technology (INCT) in Precision Intensive Care Medicine
Conditions
(from sponsor)		 Septic Shock
Related terms Critical Illness, Diabetes Insipidus, Shock, Septic
Enrollment 2,800 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov